For HIV patients with belly fat on tesamorelin, losing belly fat was linked to better muscle density in their abdominal and rectus muscles.

For people with HIV taking tesamorelin, losing belly fat was linked to thicker, denser muscles in the abdominal and rectus areas.

When belly fat went down in these patients, their trunk muscles also got less fatty—suggesting the same process might be cleaning up both types of fat.

For HIV patients with belly fat who responded to this drug, taking tesamorelin for 6 months made their trunk muscles less fatty and more dense, like turning soft muscle into firmer muscle.

HIV patients with belly fat who responded to tesamorelin saw better lean muscle quality in their abdominal and rectus muscles, with improvements of 1.39 and 1.78 units respectively compared to placebo after 26 weeks.

Tesamorelin reduced belly fat without affecting other fat or weight in HIV patients with abdominal obesity.